Consuelo Marín-Vicente leaned over her microscope in a Madrid lab, staring not just at heart cells, but at the quiet promise of regeneration hidden within them. At the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), two research teams have cracked open a new frontier in cardiac science by developing Spain’s first single-cell proteomics technique capable of analyzing individual cardiomyocytes—the muscle cells that power every heartbeat. Their breakthrough, published in Genome Biology, reveals that the transcription factor Myc doesn’t act uniformly across heart cells; instead, it sculpts a rare subpopulation with the molecular signature of regenerative potential, offering fresh hope for repairing damaged hearts.
Heart disease remains the leading cause of death worldwide, and one of its cruelest aspects is the organ’s inability to heal itself. Unlike the liver or skin, the adult mammalian heart cannot replace lost cardiomyocytes after injury like myocardial infarction. Past studies by CNIC’s Dr. Miguel Torres showed that turning on Myc—a gene involved in cell growth and division—could improve recovery in mouse hearts, but no one knew how it worked at the cellular level. Now, thanks to a pioneering method co-developed with scientists at Sweden’s Karolinska Institute, researchers can see exactly how Myc reshapes the proteome of single heart cells.
The technology combines refined cell isolation, cutting-edge mass spectrometry, and novel bioinformatics algorithms to profile the full suite of proteins in individual cardiomyocytes. What the team found was striking: Myc doesn’t trigger a uniform response. Instead, it alters metabolic enzyme levels in a cell-specific way, pushing some cardiomyocytes into a state of controlled immaturity—essentially turning back their biological clocks. These reprogrammed cells exhibit characteristics linked to proliferation and repair, marking them as a regenerative subpopulation. As first author Consuelo Marín-Vicente puts it, “Myc expression alters the levels of metabolic enzymes differently in each individual cell, generating distinct states of cellular immaturity and giving rise to a subpopulation of cardiomyocytes with regenerative potential.”
This discovery shifts the paradigm for future heart therapies. Rather than aiming to regenerate the entire heart at once, treatments could one day target or mimic this specific cell state. The implications extend beyond cardiology—this proteomic method could be adapted to study cellular diversity in cancer, neurodegeneration, and aging.
While clinical applications are still on the horizon, the study opens a precise window into how regeneration might be unlocked, one cell at a time. In a world where heart failure affects over 60 million people globally, this work doesn’t just advance science—it carries the quiet pulse of possibility.